Pulse Biosciences (PLSE) Osake Kurssi
Pulse Biosciences Kurssi
Liikevaihto on kasvanut 20,0 % vuodessa viimeisten 9 vuoden aikana 350 000,00 USD:een. Pulse Biosciencesn nettomarginaali on nyt −20 794,6 %, noussut −43 628,9 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 44,00 USD, eli ali nykyhintaa 15,8 %. 12 analyytikosta 11 suosittaa ostoa — kokonaiskonsensus on Osta.
Pulse Biosciences osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Pulse Biosciences liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Pulse Biosciences -osakkeesta
The business model of Pulse Biosciences Inc revolves around the development and commercialization of a proprietary bioelectric technology called Nano-Pulse Stimulation (NPS). NPS is designed to selectively disrupt and kill cells, with potential applications in various medical and aesthetic procedures. Pulse Biosciences aims to leverage NPS technology across multiple therapeutic areas, including dermatology, oncology, and immune-oncology. By harnessing the power of electrical energy and using it to safely and effectively treat diseases, Pulse Biosciences seeks to revolutionize the field of medicine.
Pulse Biosciences Inc is primarily active in the medical technology industry.
The main competitors of Pulse Biosciences Inc in the market include medical technology companies such as Medtronic, Johnson & Johnson, and Boston Scientific Corporation. These companies also focus on developing innovative medical devices and therapies for various healthcare applications. However, Pulse Biosciences Inc distinguishes itself through its proprietary technology known as Nano-Pulse Stimulation (NPS), which offers unique advantages in the treatment of various dermatological conditions.
Pulse Biosciences Inc., a pioneering bioelectric medicine company, was founded in 2014. Headquartered in California, it aims to improve patients' lives through its innovative Nano-Pulse Stimulation (NPS) technology. Pulse Biosciences focuses on the development and commercialization of medical devices that utilize NPS to enhance tissue interactions and treat a variety of dermatological conditions, immune-oncology, and oncology. This revolutionary technology has the potential to transform the healthcare industry by providing safe, effective, and non-thermal treatments. With its strong emphasis on research and development, Pulse Biosciences Inc. strives to redefine medical possibilities and revolutionize patient care.
Pulse Biosciences Inc has achieved several significant milestones. Firstly, the company received clearance from the U.S. Food and Drug Administration (FDA) for its Nano-Pulse Stimulation (NPS) platform, which is a breakthrough technology for treating various dermatological conditions. Additionally, Pulse Biosciences has successfully completed several clinical trials, demonstrating the safety and efficacy of its NPS platform. The company has also expanded its intellectual property portfolio, securing multiple patents to protect its innovative technology. Moreover, Pulse Biosciences has formed strategic collaborations with renowned research institutions and medical centers to further develop and commercialize its NPS platform. These achievements highlight Pulse Biosciences Inc's progress and commitment to revolutionizing dermatological treatments.
Pulse Biosciences Inc is primarily present in the United States.
Pulse Biosciences Inc represents a commitment to innovation and cutting-edge technology in the field of medical biosciences. As a leading provider of medical therapy solutions, the company emphasizes a corporate philosophy centered around delivering breakthrough treatments to patients through its proprietary technology platform, known as Nano-Pulse Stimulation (NPS). Pulse Biosciences Inc remains dedicated to advancing the field of dermatology and oncology by providing safe and effective treatment options with its non-thermal, tumor-focused approach. With its strong focus on research and development, Pulse Biosciences Inc continues to push boundaries and revolutionize the way medical therapies are delivered.
Analyytikot asettavat tällä hetkellä Pulse Biosciences-osakkeelle keskimääräisen tavoitehinnan 45,25 USD (mediaani: 44,00 USD), mikä merkitsee −13,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 12 analyytikkoarvioon.
12 analyytikkoa arvioi tällä hetkellä Pulse Biosciences-osaketta: 11 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Pulse Biosciences-yhtiöltä 2,04 M USD liikevaihtoa ja −1,19 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Pulse Biosciences-osake noteerataan hintaan 46,81 EUR (52,24 USD).
Pulse Biosciences-osake (PLSE) on listattuna 4 pörssissä, muun muassa: NASDAQ (PLSE), Frankfurt (6L8.F), München (6L8.MU), Düsseldorf (6L8.DU).
Pulse Biosciences Inc is a medical technology company specializing in the development of non-invasive devices for the treatment of skin diseases and cancer. The company has three main business segments: CellFX System, Nano-Pulse Stimulation (NPS), and Ignite platform. The CellFX System delivers short, non-thermal electrical pulses precisely to the skin for the treatment of various dermatological conditions. NPS technology is used in cancer treatment to destroy cancer cells without damaging surrounding tissue. The Ignite platform includes the PulseCheck imaging and diagnostic device for accurate diagnosis and treatment planning. Pulse Biosciences Inc aims to provide better treatment experiences for patients and doctors and plans to market and distribute its technologies worldwide.
odotettu liikevaihto Pulse Biosciences on 2,04 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Pulse Biosciences on −80,40 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Pulse Biosciences:n hinta-voitto-suhde (P/E) on tällä hetkellä −43,79. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Pulse Biosciences-osakkeen arvostusta.
Pulse Biosciences:n hinta-myynti-suhde (P/S) on tällä hetkellä 1 727,26. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Pulse Biosciences-osakkeen arvostuskennuslukuna.
Pulse Biosciences:n Eulpool-laatuscore on 4/10.
Pulse Biosciences:n ISIN on US74587B1017. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Pulse Biosciences:n WKN on A2AMY9. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Pulse Biosciences:n ticker on PLSE. Tämä pörssinoteeraus käytetään Pulse Biosciences-osakkeiden kauppaan pörssissä.
Pulse Biosciences osake
Pulse Biosciences vertaisryhmä
Pulse Biosciences Ticker
Pulse Biosciences FIGI
Kaikki tunnusluvut ja syvällinen analyysi Pulse Biosciences:sta
Meidän osakeanalyysimme Pulse Biosciences-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Pulse Biosciences:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: